Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 8/20 | 0.36 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.35 |
| ▸ | FAAH | O00519 | 5/20 | 0.35 |
| ▸ | LIPE | Q05469 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | MLNR | O43193 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30737347 | 0.92 | PRKAA2 (0.42) | HRH3PRKAA2NPC1RAB9AKMT2A | |
| SCHEMBL30737508 | 0.83 | MAPT (0.43) | HRH3LIPERAB9AKMT2ALMNA | |
| SCHEMBL30737301 | 0.80 | HRH3 (0.38) | HRH3LIPEKMT2ALMNA | |
| SCHEMBL30737459 | 0.79 | KDM4E (0.44) | HRH3KMT2A | |
| SCHEMBL30737188 | 0.79 | SORT1 (0.47) | HRH3PRKAA2FAAHKMT2ALMNA | |
| SCHEMBL30737352 | 0.73 | LMNA (0.44) | HRH3PRKAA2LIPEKMT2ALMNA | |
| SCHEMBL31646122 | 0.73 | SORT1 (0.44) | HRH3PRKAA2FAAHLIPE | |
| SCHEMBL31646579 | 0.72 | SORT1 (0.45) | HRH3PRKAA2FAAHLIPE | |
| SCHEMBL30737405 | 0.72 | PRKAA2 (0.42) | HRH3PRKAA2FAAHKMT2AKCNH2 | |
| SCHEMBL30737488 | 0.71 | MAPT (0.45) | LIPERAB9AKMT2ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250345446-A1 | BIFUNCTIONAL MOLECULES THAT SELECTIVELY INDUCE DEGRADATION OF EXTRACELLULAR TARGETS IN LYSOSOMES | DRAUPNIR BIO APS (DK) | 2025-11-13 | — | — | US | disclosed |
| EP-4543858-A1 | BIFUNCTIONAL MOLECULES THAT SELECTIVELY INDUCE DEGRADATION OF EXTRACELLULAR TARGETS IN LYSOSOMES | Draupnir Bio ApS (DK) | 2025-04-30 | — | — | EP | disclosed |
| WO-2023247754-A1 | BIFUNCTIONAL MOLECULES THAT SELECTIVELY INDUCE DEGRADATION OF EXTRACELLULAR TARGETS IN LYSOSOMES | DRAUPNIR BIO APS (DK) | 2023-12-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250345446-A1 | BIFUNCTIONAL MOLECULES THAT SELECTIVELY INDUCE DEGRADATION OF EXTRACELLULAR TARGETS IN LYSOSOMES | SORT1, SCARB1, LAMP1 | HRH3 2954/4885PRKAA2 2417/4885FAAH 4056/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.